Scott Braunstein

Scott Braunstein, MD, is the Chief Executive Officer of Marinus Pharmaceuticals and an Operating Partner at Aisling Capital, bringing over twenty years of biopharmaceutical and healthcare investing experience. Previously, he spent twelve years at JP Morgan Asset Management, serving as a managing director and portfolio manager for the JP Morgan Global Healthcare Fund. His background includes executive roles as Chief Strategy Officer and Chief Operating Officer at Pacira Pharmaceuticals, alongside working as a healthcare portfolio manager at Everpoint Asset Management. Braunstein currently serves on the board of directors for Caribou Biosciences, having been appointed in June 2021, and Trevena, and previously served on the board of Constellation Pharmaceuticals before its acquisition by MorphoSys AG. His professional focus centers on biopharmaceutical leadership, with specific expertise in advancing treatments for rare seizure disorders, cancer therapies, and CRISPR genome editing.